ZUKANORM 50 10

About

ZUKANORM 50 likely contains Sitagliptin 50mg, an oral antidiabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is used for the management of type 2 diabetes mellitus. Sitagliptin works by inhibiting the enzyme DPP-4, which is responsible for inactivating incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving the active forms of these incretins, Sitagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from pancreatic alpha cells. This dual action helps to lower both fasting and postprandial blood glucose concentrations. Sitagliptin is typically used as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents, to improve glycemic control in adults with type 2 diabetes.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as monotherapy or in combination with other antidiabetics.
• Adjunct to diet and exercise.

Directions For Use

Take orally, usually once daily, with or without food, or as directed by your healthcare provider.

Benefits

• Effective blood glucose reduction.
• Glucose-dependent insulin release.
• Suppression of glucagon secretion.
• Low risk of hypoglycemia as monotherapy.
• Weight-neutral effect.
• Well-tolerated with a convenient once-daily dose.

Side Effects

• Upper respiratory tract infection
• Nasopharyngitis (common cold)
• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Hypoglycemia (when combined with sulfonylureas or insulin)
• Joint pain
• Rash
• Pancreatitis (rare)
• Severe allergic reactions (rare)
• Kidney problems (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may affect blood sugar levels. Consult your doctor.
• Pregnancy - Not recommended during pregnancy due to insufficient data. Consult your doctor to discuss risks and benefits, and consider alternative treatments.
• Breastfeeding - It is unknown if Sitagliptin is excreted in human milk. Exercise caution and consult your doctor before use.
• Liver - No dose adjustment is typically required for mild to moderate hepatic impairment. Use with caution in severe liver disease.
• Kidney - Dose adjustment is required for moderate to severe renal impairment and end-stage renal disease. Regular monitoring of kidney function is advised.
• Lung - Generally considered safe for use in patients with lung conditions. No specific contraindications related to pulmonary function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.